Our LPT-CBD injection offers a new approach to managing chronic pain in companion animals. This innovative single injection solution provides long-lasting drug exposure and effective relief, improving the quality of life for pets.

Addressing a Growing Market

The veterinary pain management market, currently valued at $1.65 billion, is projected to exceed $2.2 billion by 2029. Companion animals represent the largest segment, comprising 85% of this market. Our innovative LPT-CBD injection is well-positioned to address the needs of this growing market.

Efficacy and Safety

Our LPT-CBD injection has demonstrated long-lasting blood CBD exposure, significant efficacy and safety in studies conducted on clinical companion dogs focused on chronic pain conditions:

• Osteoarthritis and cervical pain in a dog (case report): As part of compassionate care, a single subcutaneous injection of LPT-CBD improved pain and activity for up to 3 weeks 
• Osteoarthritis-related Pain in dogs: A single subcutaneous injection of LPT-CBD provided long-term analgesic effects, lasting several weeks
• Pharmacokinetics in dogs: A single LPT-CBD injection maintained CBD plasma concentrations for up to 6 weeks
• Basic Safety in dogs: Safety monitoring, including vital signs, hematology, and serum biochemistry, showed excellent tolerance of LPT-CBD

Regulatory Progress

The FDA’s Center for Veterinary Medicine (CVM) has granted a fee waiver and assigned an Investigational New Animal Drug (INAD) number for our LPT-CBD product, as part of our regulatory pathway.

Commitment to Animal Health

At Innocan, we are dedicated to improving the lives of companion animals through scientific innovation. LPT-CBD addresses real clinical needs, providing significant pain relief for pets with chronic pain.

Discover how Innocan is making strides in veterinary pain management with our LPT-CBD injection.